What is the ticker symbol for Rani Therapeutics?

Rani Therapeutics trades under the ticker RANI on NASDAQ.

What sector does Rani Therapeutics operate in?

Rani Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze RANI in a portfolio?

PortView shows RANI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Rani Therapeutics (RANI) Stock Analysis

NASDAQHealthcareBiotechnology

$0.61-0.28%

1-year price historyRange $0.59 – $2.50

52-week range$0.61

$0.57$2.63

Track RANI in your portfolio for free · Portfolio tracker

What Rani Therapeutics does

Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.

Key metrics

Market cap

$39.69M

P/E (TTM)

-2.25

EPS (TTM)

$-0.27

Beta

0.71

Dividend yield

0.00%

Revenue / share

$0.03

50-day avg

$0.78

200-day avg

$0.95

52-week high

$2.63

52-week low

$0.57

CEO

Talat Imran

ETFs linked to RANI

Broad-market and Healthcare sector ETFs an investor holding Rani Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how RANI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze RANI in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Rani Therapeutics?: Rani Therapeutics trades under the ticker RANI on NASDAQ.
Which exchange is RANI listed on?: RANI is listed on NASDAQ.
What sector does Rani Therapeutics operate in?: Rani Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze RANI in a portfolio?: PortView shows RANI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.